Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4531| Title: | SARS-CoV-2 vaccination in patients with inflammatory bowel disease | Authors: | Connor, S. J. Ghaly, S. Christensen, B. Prentice, R. E. Rentsch, C. Al-Ani, A. H. Zhang, E. Johnson, D. Halliday, J. Bryant, R. Begun, J. Ward, M. G. Lewindon, P. J. |
Issue Date: | 2021 | Source: | 3, (4), 2021, p. 212-228 | Pages: | 212-228 | Journal: | GastroHep | Abstract: | Background: The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions. Aim: This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD. Methods: All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised. Results: Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited. Conclusions: SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.L20132569262021-07-29 | DOI: | 10.1002/ygh2.473 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2013256926&from=exporthttp://dx.doi.org/10.1002/ygh2.473 | | Keywords: | drug efficacy;drug industry;drug safety;fatigue;fever;headache;human;immunity;immunosuppressive treatment;inflammatory bowel disease;injection site reaction;malaise;myalgia;pediatrics;phase 1 clinical trial (topic);phase 2 clinical trial (topic);phase 3 clinical trial (topic);phase 4 clinical trial (topic);physician;practice guideline;pregnancy;review;risk factor;Severe acute respiratory syndrome coronavirus 2;vaccination;vaccine-induced immune thrombotic thrombocytopenia;ad26cov2s;ad5ncov;azd1222;bbibp corv;mrna 1273;nvx cov2373;bnt162b2;ad26.cov2.s vaccinecovilo;tozinameran;convidicea;coronavac;corticosteroid;covaxin;elasomeran;epivaccorona;immunomodulating agent;mesalazine;nvx-cov2373 vaccine;sputnik v;sputnik v vaccine;tofacitinib;tumor necrosis factor inhibitor;ustekinumab;vaxzevria;vedolizumab;anaphylaxis;arthralgia;breast feeding;cerebral sinus thrombosis;chill;coronavirus disease 2019;counseling | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.